Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: Oral Oncol. 2022 Mar 23;128:105806. doi: 10.1016/j.oraloncology.2022.105806

Table 3.

Summary of patient characteristics, best overall response, duration of response, reason for discontinuation, and molecular testing among patients in the therapeutic study.

Patient Tumor type Prior lines ofchemotherapy Best overall response Best responseby RECIST, % Treatmentduration, days Reason for discontinuing study Molecular testing
1 Oropharynx 5 SD −6 222 Disease progression ASXL1; DNMT3B; ATR; EP300; MLL3; PIK3R1
2 Anal 1 SD 6 59 Withdrawal of consenta Not performed
3 Cervix 3 SD 8 39 Toxicity(anemia) PIK3CA; SOX2; EIF4A2; TP63; BLM; FBXW7; FGFR1; GRIN2A; MGA; MLL2; NUP93; PAK7; RAD51C; RPTOR; SMO; SUFU; TSC2
4 Anal 2 POD 39 27 Disease progression TP63; CTNNB1
5 Anal 2 SD −1 55 Progression (nontarget lesion) PIK3CA; B2M; BRAF; CRKL; EP300; ERG; KDM6A; LATS2; MLL3; PIK3C3; RYBP; STAG2; TETI
6b Oropharynx 3 – – 27 Clinical decline (pain) ERBB2; TP63; DICER1; MDC1; NOTCH1; ATR
7b Anal 6 SD 1 27 Withdrawal of consenta PIK3CA
8 Anal 2 SD 3 173 Disease progression PIK3CA, GNA11; TGFBR2; ANKRD11; DICER1; DIS3; SPEN; KDM6A
9 Cervix 3 POD 0 19 Progression (nontarget lesion) Not performed
10 Oropharynx 4 POD 5 29 Disease progression GSK3B
11b Oropharynx 5 – – 19 Withdrawal of consenta PIK3CA; FBXW7; FOXA1; PTEN
12 Cervix 2 POD −1 41 Progression (nontarget lesion) Not performed

POD, progression of disease; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.

a

Reasons for consent withdrawal: Patient 2: rectal bleeding; Patient 7: radiographic progression not meeting RECIST criteria; Patient 11: clinical decline.

b

Inevaluable for response: Patients 6 and 11: no interval imaging was performed; Patient 7: radiographic progression not meeting RECIST criteria, incomplete cycle.